A carregar...
BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
Imatinib, the first-in-class BCR-ABL tyrosine kinase inhibitor (TKI), had been a revolution for the treatment of chronic myeloid leukemia (CML) and had greatly enhanced patient survival. Second- (dasatinib, nilotinib, and bosutinib) and third-generation (ponatinib) TKIs have been developed to be eff...
Na minha lista:
| Publicado no: | TH Open |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Georg Thieme Verlag KG
2018
|
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6524858/ https://ncbi.nlm.nih.gov/pubmed/31249931 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1055/s-0038-1624566 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|